<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:38:28Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10600583" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10600583</identifier>
        <datestamp>2023-10-27</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10600583</article-id>
              <article-id pub-id-type="pmcid">PMC10600583</article-id>
              <article-id pub-id-type="pmc-uid">10600583</article-id>
              <article-id pub-id-type="pmid">37878313</article-id>
              <article-id pub-id-type="pmid">37878313</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.39584</article-id>
              <article-id pub-id-type="publisher-id">zoi231155</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Oncology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival</article-title>
                <alt-title alt-title-type="headline">Age, BMI, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer</alt-title>
                <alt-title alt-title-type="running-head">Age, BMI, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lipsyc-Sharf</surname>
                    <given-names>Marla</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi231155aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi231155aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi231155aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ballman</surname>
                    <given-names>Karla V.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi231155aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Campbell</surname>
                    <given-names>Jordan D.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi231155aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Muss</surname>
                    <given-names>Hyman B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi231155aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perez</surname>
                    <given-names>Edith A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi231155aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shulman</surname>
                    <given-names>Lawrence N.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi231155aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carey</surname>
                    <given-names>Lisa A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi231155aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Partridge</surname>
                    <given-names>Ann H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi231155aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi231155aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Warner</surname>
                    <given-names>Erica T.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="zoi231155aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi231155aff1"><label>1</label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts</aff>
              <aff id="zoi231155aff2"><label>2</label>Harvard Medical School, Boston, Massachusetts</aff>
              <aff id="zoi231155aff3"><label>3</label>David Geffen School of Medicine at UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, California</aff>
              <aff id="zoi231155aff4"><label>4</label>Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota</aff>
              <aff id="zoi231155aff5"><label>5</label>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill</aff>
              <aff id="zoi231155aff6"><label>6</label>Mayo Clinic Cancer Center, Jacksonville, Florida</aff>
              <aff id="zoi231155aff7"><label>7</label>Abramson Cancer Center, University of Pennsylvania, Philadelphia</aff>
              <aff id="zoi231155aff8"><label>8</label>Clinical Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Boston</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> September 11, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> October 25, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.39584</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. Â© 2023 Lipsyc-Sharf M et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi231155cor1"><bold>Corresponding Author:</bold> Erica T. Warner, ScD, Massachusetts General Hospital, 100 Cambridge St, Bartlett 9, Boston, MA 02114 (<email xlink:href="EWarner@mgh.harvard.edu">EWarner@mgh.harvard.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Campbell and Ballman had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Ballman, Shulman, Partridge, Warner.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Ballman, Campbell, Muss, Perez, Carey, Partridge, Warner.</p>
                <p><italic>Drafting of the manuscript:</italic> Ballman, Campbell, Muss, Warner.</p>
                <p><italic>Critical review of the manuscript for important intellectual content:</italic> Muss, Perez, Shulman, Carey, Partridge, Warner.</p>
                <p><italic>Statistical analysis:</italic> Ballman, Campbell, Muss.</p>
                <p><italic>Administrative, technical, or material support:</italic> Shulman.</p>
                <p><italic>Supervision:</italic> Muss, Carey, Partridge, Warner.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Lipsyc-Sharf reported receiving grants from the American Society of Clinical Oncology Conquer Cancer Foundation and the Terri Brodeur Breast Cancer Foundation and receiving honoraria from MJH Life Sciences outside the submitted work. Dr Ballman reported receiving grants from the National Cancer Institute during the conduct of the study as well as serving as an expert witness for Janssen Oncology, Sanofi, and Easai and serving on the data safety monitoring board for Agenus and Takeda outside the submitted work. Dr Shulman reported receiving grant support from the Breast Cancer Research Foundation and consulting fees from Genentech. Dr Warner reported receiving grants from Pfizer outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Nos. U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA232760, UG1CA233180, and UG1CA233373.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The National Cancer Institute is a sponsor and helped with the design of the study and review of the manuscript. The National Cancer Institute was not involved in the conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
                <p><bold>Meeting Presentation:</bold> These data were shared, in part, in a poster presented at the American Association for Cancer Research Conference 2022; April 8 to 13, 2022; New Orleans, Louisiana.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI231155-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-10-25T10:00">
                <day>25</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>25</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>10</issue>
              <elocation-id>e2339584</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>6</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Lipsyc-Sharf M et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2339584.pdf">jamanetwopen-e2339584.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.39584"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi231155-1">
                  <title>Question</title>
                  <p>Are there racial and ethnic disparities in survival among participants enrolled in clinical trials receiving standardized initial care for early-stage breast cancer?</p>
                </sec>
                <sec id="ab-zoi231155-2">
                  <title>Findings</title>
                  <p>In this cohort study with 9479 participants, pooled survival data suggest that survival differences exist even within clinical trial participants receiving similar initial care. Subgroups, defined by tumor subtype, age, and/or body mass index, that may drive racial and ethnic disparities in survival were identified.</p>
                </sec>
                <sec id="ab-zoi231155-3">
                  <title>Meaning</title>
                  <p>These findings suggest potential factors contributing to racial and ethnic disparities in survival of patients with breast cancer; it is critical to evaluate interventions for improvement.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This cohort study assesses the association of race and ethnicity with survival among clinical trial participants with early-stage breast cancer according to tumor subtype, age, and body mass index (BMI).</p>
              </abstract>
              <abstract>
                <sec id="ab-zoi231155-4">
                  <title>Importance</title>
                  <p>Black women in the United States have higher breast cancer (BC) mortality rates than White women. The combined role of multiple factors, including body mass index (BMI), age, and tumor subtype, remains unclear.</p>
                </sec>
                <sec id="ab-zoi231155-5">
                  <title>Objective</title>
                  <p>To assess the association of race and ethnicity with survival among clinical trial participants with early-stage BC (eBC) according to tumor subtype, age, and BMI.</p>
                </sec>
                <sec id="ab-zoi231155-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This cohort study analyzed survival data, as of November 12, 2021, from participants enrolled between 1997 and 2010 in 4 randomized adjuvant chemotherapy trials: Cancer and Leukemia Group B (CALGB) 9741, 49907, and 40101 as well as North Central Cancer Treatment Group (NCCTG) N9831, legacy groups of the Alliance of Clinical Trials in Oncology. Median follow-up was 9.8 years.</p>
                </sec>
                <sec id="ab-zoi231155-7">
                  <title>Exposures</title>
                  <p>Non-Hispanic Black and Hispanic participants were compared with non-Hispanic White participants within subgroups of subtype (hormone receptor positive [HR+]/<italic>ERBB2 </italic>[formerly <italic>HER2</italic>] negative [<italic>ERBB2</italic>â], <italic>ERBB2</italic>+, and HRâ/<italic>ERBB2</italic>â), age (&lt;50, 50 to &lt;65, and â¥65 years), and BMI (&lt;18.5, 18.5 to &lt;25.0, 25.0 to &lt;30.0, and â¥30.0).</p>
                </sec>
                <sec id="ab-zoi231155-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Recurrence-free survival (RFS) and overall survival (OS).</p>
                </sec>
                <sec id="ab-zoi231155-9">
                  <title>Results</title>
                  <p>Of 9479 participants, 436 (4.4%) were Hispanic, 871 (8.8%) non-Hispanic Black, and 7889 (79.5%) non-Hispanic White. The median (range) age was 52 (19.0-89.7) years. Among participants with HR+/<italic>ERBB2</italic>â tumors, non-Hispanic Black individuals had worse RFS (hazard ratio [HR], 1.49; 95% CI, 1.04-2.12; 5-year RFS, 88.5% vs 93.2%) than non-Hispanic White individuals, although the global test for association of race and ethnicity with RFS was not significant within any tumor subtype. There were no OS differences by race and ethnicity in any subtype. Race and ethnicity were associated with OS in young participants (age &lt;50 years; global <italic>P</italic>â=â.008); young non-Hispanic Black participants (HR, 1.34; 95% CI, 1.04-1.71; 5-year OS, 86.6% vs 92.0%) and Hispanic participants (HR, 1.62; 95% CI, 1.16-2.29; 5-year OS, 86.2% vs 92.0%) had worse OS than young non-Hispanic White participants. Race and ethnicity were associated with RFS in participants with BMIs of 25 to less than 30, with non-Hispanic Black participants having worse RFS (HR, 1.81; 95% CI, 1.23-2.68; 5-year RFS, 83.2% vs 87.3%) than non-Hispanic White participants.</p>
                </sec>
                <sec id="ab-zoi231155-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this cohort study, racial and ethnic survival disparities were identified in patients with eBC receiving standardized initial care, and potentially at-risk subgroups, for whom focused interventions may improve outcomes, were found.</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI231155">
              <title>Introduction</title>
              <p>For several decades, non-Hispanic Black women have had substantially higher breast cancer (BC) mortality rates than non-Hispanic White women.<sup><xref rid="zoi231155r1" ref-type="bibr">1</xref>,<xref rid="zoi231155r2" ref-type="bibr">2</xref>,<xref rid="zoi231155r3" ref-type="bibr">3</xref>,<xref rid="zoi231155r4" ref-type="bibr">4</xref>,<xref rid="zoi231155r5" ref-type="bibr">5</xref>,<xref rid="zoi231155r6" ref-type="bibr">6</xref>,<xref rid="zoi231155r7" ref-type="bibr">7</xref></sup> Recent data from the Surveillance, Epidemiology, and End Results program show that between 2015 and 2019, Black women had 41% higher BC mortality compared with White women despite a 4% lower incidence of BC.<sup><xref rid="zoi231155r8" ref-type="bibr">8</xref></sup> The emergence and subsequent widening of this disparity over the past 40 years suggests that potentially modifiable and time-varying factors contribute.<sup><xref rid="zoi231155r1" ref-type="bibr">1</xref></sup> Such disparities are also known to exist among Hispanic women, although there is a relative dearth of literature studying this important population.<sup><xref rid="zoi231155r9" ref-type="bibr">9</xref>,<xref rid="zoi231155r10" ref-type="bibr">10</xref>,<xref rid="zoi231155r11" ref-type="bibr">11</xref></sup> While lack of quality and timely initial adjuvant treatment is an important contributor, prospective study of BC survival in patients receiving standardized adjuvant therapy, as in the clinical trial setting, can facilitate identification of other factors.<sup><xref rid="zoi231155r10" ref-type="bibr">10</xref>,<xref rid="zoi231155r11" ref-type="bibr">11</xref>,<xref rid="zoi231155r12" ref-type="bibr">12</xref></sup></p>
              <p>A previous pooled analysis of SWOG clinical trials showed that, while no racial disparities were observed for most cancer types, non-Hispanic Black women with BC were more likely to die than non-Hispanic White women.<sup><xref rid="zoi231155r13" ref-type="bibr">13</xref></sup> While this study did not investigate potential contributing factors, subsequent studies have suggested that racial and ethnic differences in BC survival vary by tumor subtype.<sup><xref rid="zoi231155r14" ref-type="bibr">14</xref>,<xref rid="zoi231155r15" ref-type="bibr">15</xref>,<xref rid="zoi231155r16" ref-type="bibr">16</xref>,<xref rid="zoi231155r17" ref-type="bibr">17</xref></sup> Age has also been associated with survival in patients with BC. Both younger and older age have been associated with differences in treatments and adherence as well as worse mortality.<sup><xref rid="zoi231155r18" ref-type="bibr">18</xref>,<xref rid="zoi231155r19" ref-type="bibr">19</xref>,<xref rid="zoi231155r20" ref-type="bibr">20</xref>,<xref rid="zoi231155r21" ref-type="bibr">21</xref>,<xref rid="zoi231155r22" ref-type="bibr">22</xref></sup> Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) has also been shown to be associated with BC survival, although the role of BMI in racial and ethnic survival disparities, particularly among groups that are underreported and underrepresented in clinical trials, such as Hispanic patients, merits additional study.<sup><xref rid="zoi231155r20" ref-type="bibr">20</xref>,<xref rid="zoi231155r21" ref-type="bibr">21</xref>,<xref rid="zoi231155r23" ref-type="bibr">23</xref>,<xref rid="zoi231155r24" ref-type="bibr">24</xref>,<xref rid="zoi231155r25" ref-type="bibr">25</xref>,<xref rid="zoi231155r26" ref-type="bibr">26</xref></sup> In general, the extent of disparities within subgroups defined by of age, BMI, and tumor subtype are unclear yet likely are important in addressing BC. In this pooled analysis of 4 prospective adjuvant BC clinical trials, we assessed whether race and ethnicity were associated with recurrence-free survival (RFS) and overall survival (OS) among women enrolled in clinical trials for early-stage BC (eBC) according to tumor subtype, age, and BMI.<sup><xref rid="zoi231155r14" ref-type="bibr">14</xref>,<xref rid="zoi231155r15" ref-type="bibr">15</xref>,<xref rid="zoi231155r16" ref-type="bibr">16</xref>,<xref rid="zoi231155r17" ref-type="bibr">17</xref>,<xref rid="zoi231155r20" ref-type="bibr">20</xref>,<xref rid="zoi231155r21" ref-type="bibr">21</xref>,<xref rid="zoi231155r24" ref-type="bibr">24</xref>,<xref rid="zoi231155r25" ref-type="bibr">25</xref></sup></p>
            </sec>
            <sec id="H1-2-ZOI231155">
              <title>Methods</title>
              <sec id="H2-1-ZOI231155">
                <title>Data and Patients</title>
                <p>We included participants enrolled in 4 adjuvant chemotherapy trials: Cancer and Leukemia Group B (CALGB) C9741 (<ext-link xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT00003088" ext-link-type="uri">NCT00003088</ext-link>), C49907 (<ext-link xlink:href="https://clinicaltrials.gov/study/NCT00005970" ext-link-type="uri">NCT00005970</ext-link>), C40101 (<ext-link xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT00024102" ext-link-type="uri">NCT00024102</ext-link>) and North Central Cancer Treatment Group (NCCTG) N9831 (<ext-link xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT00041119" ext-link-type="uri">NCT00041119</ext-link>) (eMethods in <xref rid="note-ZOI231155-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi231155r27" ref-type="bibr">27</xref>,<xref rid="zoi231155r28" ref-type="bibr">28</xref>,<xref rid="zoi231155r29" ref-type="bibr">29</xref>,<xref rid="zoi231155r30" ref-type="bibr">30</xref></sup> CALGB and NCCTG are now part of the Alliance for Clinical Trials in Oncology (Alliance). All participants with available survival and race and ethnicity data were included (<xref rid="zoi231155f1" ref-type="fig">Figure 1</xref>). Three of the trials (CALGB 9741, CALGB 49907, and CALGB 40101) evaluated adjuvant chemotherapy regimens for all BC subtypes, while NCCTG N9831 included only patients with human epidermal growth factor receptor 2âpositive (<italic>ERBB2</italic>+) BC. CALGB 49907 studied older women with BC and included only patients ages 65 years and older. Relevant ethical review committees approved all trials. All participants in these trials provided informed consent. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline.</p>
                <fig position="float" id="zoi231155f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Flow Diagram of Participants</title>
                    <p>CALGB indicates Cancer and Leukemia Group B; NCCTG, North Central Cancer Treatment Group.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2339584-g001" position="float"/>
                </fig>
              </sec>
              <sec id="H2-2-ZOI231155">
                <title>Measures and Outcomes</title>
                <p>Tumor hormone receptor (HR) and <italic>ERBB2</italic> status were assessed in each trial as previously published.<sup><xref rid="zoi231155r27" ref-type="bibr">27</xref>,<xref rid="zoi231155r28" ref-type="bibr">28</xref>,<xref rid="zoi231155r29" ref-type="bibr">29</xref>,<xref rid="zoi231155r30" ref-type="bibr">30</xref></sup> In this study, we analyzed the following subtypes: hormone receptorâpositive/<italic>ERBB2</italic>-negative (HR+/<italic>ERBB2</italic>â), <italic>ERBB2</italic>+, and HR-negative/<italic>ERBB2</italic>-negative (HRâ/ERBB2â; also known as triple negative). Race and ethnicity were analyzed in 4 groups: Hispanic, non-Hispanic Black, non-Hispanic White, and other race and ethnicity (including American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander). The other race and ethnicity group was created because the sample sizes of the individual groups were too small to analyze separately. Race and ethnicity were patient-reported based on investigator options in 2 of the 4 trials included. For the other 2 trials, documentation of how race and ethnicity were collected is not available. Age at diagnosis was divided into 3 groups: younger than 50 years, 50 to younger than 65 years, and 65 years or older. Participant BMI at time of trial randomization was separated into 4 groups: less than 18.5, 18.5 to less than 25.0, 25.0 to less than 30.0, and 30.0 or greater, corresponding to the US Center for Disease Control and Prevention definitions of underweight, healthy weight, overweight, and obesity, respectively.<sup><xref rid="zoi231155r31" ref-type="bibr">31</xref></sup></p>
                <p>RFS events included local, regional, or distant BC recurrence or death due to any cause.<sup><xref rid="zoi231155r32" ref-type="bibr">32</xref></sup> Participants alive without an RFS event were censored at the time of last follow-up. OS was defined using deaths from any cause as an event. Participants without known death were censored at the time of last contact, including any participants lost to follow-up. All time-to-event measures started at the time of trial randomization.</p>
              </sec>
              <sec id="H2-3-ZOI231155">
                <title>Statistical Analysis</title>
                <p>Median follow-up was estimated using the reverse Kaplan-Meier method.<sup><xref rid="zoi231155r33" ref-type="bibr">33</xref>,<xref rid="zoi231155r34" ref-type="bibr">34</xref>,<xref rid="zoi231155r35" ref-type="bibr">35</xref></sup> Baseline characteristics between race and ethnicity groups were compared using a Ï<sup>2</sup> test.<sup><xref rid="zoi231155r36" ref-type="bibr">36</xref></sup> All results presented are multivariable analyses. Cox proportional hazards models were used to estimate multivariable-adjusted hazard ratios (HRs) and 95% CIs for the association between race and ethnicity and RFS or OS.<sup><xref rid="zoi231155r34" ref-type="bibr">34</xref>,<xref rid="zoi231155r35" ref-type="bibr">35</xref></sup> Multivariable models included race and ethnicity, tumor subtype, BMI, age, stage, and treatment group if the variable was not the subgroup being evaluated. Participants with missing data for subtype or stage were not included in the multivariable analyses controlling for subtype or stage, respectively. We also conducted separate analyses within strata of age and strata of BMI. Participants with missing data for BMI were not included in analyses within strata of BMI. No participants had missing age data. <italic>P</italic> values are provided only for global tests and not for comparisons of different levels of the variable with the reference group. We present point estimates and 95% CIs comparing each level of the variable with the reference group. Results of analyses were also depicted with forest plots.<sup><xref rid="zoi231155r37" ref-type="bibr">37</xref></sup> Kaplan-Meier estimators were used to estimate survival at specific time points and to generate survival curves.<sup><xref rid="zoi231155r34" ref-type="bibr">34</xref>,<xref rid="zoi231155r35" ref-type="bibr">35</xref></sup> The prespecified level of significance was .05. The Alliance Statistics and Data Management Center conducted statistical analyses on the study database frozen on November 12, 2021, using SAS version 9.3 (SAS Institute).</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI231155">
              <title>Results</title>
              <sec id="H2-4-ZOI231155">
                <title>Patient Characteristics</title>
                <p>Of 10â011 women enrolled in the included trials, 9479 (94.7%) had available survival and race and ethnicity data and were included in this pooled analysis. Their median (IQR) follow-up time was 9.8 (6.7-13.2) years, and 435 participants (4.6%) were designated as lost to follow-up. All participants were female. There were 436 (4.6%) Hispanic, 871 (9.2%) non-Hispanic Black, 7889 (83.2%) non-Hispanic White participants, and 283 (3.0%) patients with another race and ethnicity (<xref rid="zoi231155t1" ref-type="table">Table</xref>). At enrollment, median (range) age was 52 (19.0-89.7) years, and median (range) BMI was 28.3 (12.3-77.3). The distribution of tumor subtypes differed significantly among race and ethnicity groups, with a larger proportion of non-Hispanic Black participants with HRâ/<italic>ERBB2</italic>â BC compared with non-Hispanic White participants (197 [25.6%] vs 1049 [14.7%]; <italic>P</italic>â&lt;â.001). Additionally, BMI differed significantly across race and ethnicity groups; obesity was more frequent in non-Hispanic Black participants than non-Hispanic White participants (511 [59.5%] vs 3008 [38.7%]; <italic>P</italic>â&lt;â.001). The baseline characteristics between Hispanic and non-Hispanic White participants were similar.</p>
                <table-wrap position="float" id="zoi231155t1">
                  <label>Table. </label>
                  <caption>
                    <title>Participant Baseline Characteristics</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="19.75%" span="1"/>
                    <col width="14.31%" span="1"/>
                    <col width="16.84%" span="1"/>
                    <col width="17.58%" span="1"/>
                    <col width="17.35%" span="1"/>
                    <col width="14.17%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%)</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Hispanic (nâ=â436)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Non-Hispanic Black (nâ=â871)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Non-Hispanic White (nâ=â7889)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Non-Hispanic other (nâ=â283)<xref rid="zoi231155t1n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Total (Nâ=â9479)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Trial</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CALGB 40101</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">206 (47.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">357 (41.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2865 (36.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">95 (33.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3523 (37.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CALGB 49907</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (6.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">59 (6.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">460 (5.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (3.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">559 (5.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CALGB 9741</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">80 (18.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">216 (24.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1625 (20.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (13.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1960 (20.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> NCCTG N9831</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">120 (27.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">239 (27.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2939 (37.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">139 (49.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3437 (36.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age category, y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;50</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">212 (48.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">424 (48.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3285 (41.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">138 (48.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4059 (42.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 50 to &lt;65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">162 (37.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">335 (38.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3385 (42.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">109 (38.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3991 (42.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> â¥65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62 (14.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">112 (12.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1219 (15.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">36 (12.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1429 (15.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Stage</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> I</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">113 (26.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">177 (20.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1798 (22.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52 (18.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2140 (22.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> II</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">268 (62.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">533 (61.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4823 (61.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">186 (66.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5810 (61.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> III</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">50 (11.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">152 (17.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1225 (15.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40 (14.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1467 (15.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">62</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Breast cancer subtype</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>ERBB2</italic>+</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">172 (43.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">320 (41.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3376 (47.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">152 (59.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4020 (47.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HR+/<italic>ERBB2</italic>â</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">141 (35.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">252 (32.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2711 (38.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">72 (28.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3176 (37.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HRâ/<italic>ERBB2</italic>â</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">83 (21.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">197 (25.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1049 (14.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (12.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1362 (15.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">102</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">753</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">921</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">BMI category<xref rid="zoi231155t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Underweight</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (0.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (0.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">129 (1.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (1.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">146 (1.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Healthy weight</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">92 (21.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">112 (13.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2315 (29.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">115 (40.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2634 (28.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Overweight</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">146 (33.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">228 (26.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2328 (29.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">96 (34.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2798 (29.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Obesity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">189 (43.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">511 (59.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3008 (38.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66 (23.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3774 (40.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">109</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">127</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: â, negative; +, positive; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CALGB, Cancer and Leukemia Group B; HR, hormone receptor; NCCTG, North Central Cancer Treatment Group.</p>
                    <fn id="zoi231155t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Other race and ethnicity includes American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander.</p>
                    </fn>
                    <fn id="zoi231155t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>BMI groups were determined based on Center for Disease Control and Prevention definitions of underweight, healthy weight, overweight, and obesity as follows: less than 18.5, 18.5 to less than 25.0, 25.0 to less than 30.0, and 30.0 or greater respectively.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-5-ZOI231155">
                <title>Survival and Race and Ethnicity</title>
                <sec id="H3-1-ZOI231155">
                  <title>Survival Within Tumor Subtypes by Race and Ethnicity</title>
                  <p>We evaluated differences in RFS and OS among racial and ethnic groups for participants with the same BC subtype. Of all 9479 participants, 8588 (90.6%) had available tumor subtype data and were included in these analyses. Global tests for the association of the race and ethnicity variable with tumor subtype were not statistically significant within any subtype. However, we did observe an association among participants with HR+/<italic>ERBB2</italic>â tumors, with non-Hispanic Black individuals having worse RFS than non-Hispanic White individuals (HR, 1.49; 95% CI, 1.04-2.12; 5-year RFS, 88.5% vs 93.2%) (<xref rid="zoi231155f2" ref-type="fig">Figure 2</xref>). There were no differences in RFS observed between non-Hispanic Black and non-Hispanic White participants among those with <italic>ERBB2</italic>+ tumors (HR, 0.98; 95% CI, 0.75-1.30; 5-year RFS, 84.0% vs 85.1%) or HRâ/<italic>ERBB2</italic>â tumors (HR, 1.28; 95% CI, 0.85-1.92; 5-year RFS, 84.1% vs 86.6%). There were no differences in RFS between Hispanic and non-Hispanic White participants, and no OS differences by race and ethnicity in any tumor subtype. Kaplan-Meier estimates of RFS and OS in BC subtype by race and ethnicity are depicted in eFigure 1 and eFigure 2 in <xref rid="note-ZOI231155-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
                  <fig position="float" id="zoi231155f2" fig-type="figure">
                    <label>Figure 2. </label>
                    <caption>
                      <title>Forest Plots of Hazard Ratios Comparing Survival in Tumor Subtype by Race/Ethnicity</title>
                      <p>â Indicates negative; +, positive; HR, hormone receptor; OS, overall survival; and RFS, recurrence-free survival.</p>
                    </caption>
                    <graphic xlink:href="jamanetwopen-e2339584-g002" position="float"/>
                  </fig>
                </sec>
                <sec id="H3-2-ZOI231155">
                  <title>Survival Within Age Categories by Race and Ethnicity</title>
                  <p>We next evaluated survival differences within age groups. All 9479 participants had available age data and were included in these analyses. Within the middle age group, ages 50 to younger than 65 years, race and ethnicity were associated with RFS (global <italic>P</italic>â=â.04); non-Hispanic Black participants had worse RFS than non-Hispanic White participants (HR, 1.37; 95% CI, 1.03-1.83; 5-year RFS, 84.6% vs 89.1%) (<xref rid="zoi231155f3" ref-type="fig">Figure 3</xref>). Among younger (ages &lt;50 years) and older (ages â¥65 years) patients, race and ethnicity were not significantly associated with RFS (global <italic>P</italic>â=â.07 and global <italic>P</italic>â=â.09, respectively). Both younger and older Hispanic participants had worse RFS than non-Hispanic White participants (younger: HR, 1.52; 95% CI, 1.09-2.10; 5-year RFS, 82.6% vs 85.9%; older: HR, 2.00; 95% CI, 1.13-3.54; 5-year RFS, 78.0% vs 87.9%). Race and ethnicity were significantly associated with OS in young participants (global <italic>P</italic>â=â.008). Specifically, young non-Hispanic Black (HR, 1.34; 95% CI, 1.04-1.71; 5-year OS, 86.6% vs 92.0%) and Hispanic (HR, 1.62; 95% CI, 1.16-2.29; 5-year OS, 86.2% vs 92.0%) participants had worse OS than young non-Hispanic White participants. There was no notable association observed between race and ethnicity and OS among participants ages 50 and older. Kaplan-Meier estimates of RFS and OS in age category by race and ethnicity are depicted in eFigure 3 and eFigure 4 in <xref rid="note-ZOI231155-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
                  <fig position="float" id="zoi231155f3" fig-type="figure">
                    <label>Figure 3. </label>
                    <caption>
                      <title>Forest Plots of Hazard Ratios Comparing Survival in Age Category by Race/Ethnicity</title>
                      <p>OS indicates overall survival; RFS, recurrence-free survival.</p>
                    </caption>
                    <graphic xlink:href="jamanetwopen-e2339584-g003" position="float"/>
                  </fig>
                  <p>When further analyzed within subgroups jointly defined by subtype and age, race and ethnicity were associated with RFS in older participants with HR+/<italic>ERBB2</italic>â BCs (global <italic>P</italic>â=â.002). Among participants ages 65 years or older with HR+/<italic>ERBB2</italic>â tumors (nâ=â696), Hispanic participants (nâ=â23) had more than 6 times the risk of having an RFS event than non-Hispanic White participants (nâ=â537) (HR, 6.30; 95% CI, 2.41-16.50). Although the global test was not statistically significant for participants younger than 50 years with HR+/<italic>ERBB2</italic>â for RFS (<italic>P</italic>â=â.06) (nâ=â1288), non-Hispanic Black participants (nâ=â103) had considerably worse RFS (HR, 1.98; 95% CI, 1.15-3.42) than non-Hispanic White participants. This was also observed for OS with a nonâstatistically significant global test (<italic>P</italic>â=â.15) but with a considerably worse OS for non-Hispanic Black participants compared with non-Hispanic White participants (HR, 1.86; 95% CI, 1.08-3.18).</p>
                </sec>
                <sec id="H3-3-ZOI231155">
                  <title>Survival Within BMI Categories by Race and Ethnicity</title>
                  <p>We also studied survival differences between race and ethnicity groups within BMI categories. Of all 9479 participants, 9352 (98.7%) had available BMI data and were included in these analyses. For participants with underweight and obesity, race and ethnicity were not significantly associated with RFS or OS on global testing. However, among participants with overweight, race and ethnicity were significantly associated with RFS (global <italic>P</italic>â=â.02), with Hispanic participants having worse RFS than non-Hispanic White participants (HR, 1.81; 95% CI, 1.23-2.68; 5-year RFS, 83.7% vs 87.3%) (<xref rid="zoi231155f4" ref-type="fig">Figure 4</xref>). For those with healthy weight, the association between race and ethnicity and RFS was not significant, although there was a significant association between race and ethnicity and OS (global <italic>P</italic>â=â.01): both non-Hispanic Black and Hispanic participants had worse OS than non-Hispanic White participants (non-Hispanic Black: HR, 1.58; 95% CI, 1.07-2.36; 5-year OS, 85.7% vs 91.5%; Hispanic: HR, 1.97; 95% CI, 1.16-3.32; 5-year OS, 85.0% vs 91.5%). Kaplan-Meier estimates of RFS and OS in BMI category by race and ethnicity are depicted in eFigure 5 and eFigure 6 in <xref rid="note-ZOI231155-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
                  <fig position="float" id="zoi231155f4" fig-type="figure">
                    <label>Figure 4. </label>
                    <caption>
                      <title>Forest Plots of Hazard Ratios Comparing Survival in Body Mass Index Category by Race/Ethnicity</title>
                      <p>Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) groups were determined based on Center for Disease Control and Prevention definitions of underweight, healthy weight, overweight, and obesity as follows less than 18.5, 18.5 to less than 25.0, 25.0 to less than 30.0, and 30.0 or greater, respectively. Point estimates and 95% CIs for overall survival (OS) of participants in the non-Hispanic other race and ethnicity group with underweight could not be estimated. RFS indicates recurrence-free survival.</p>
                    </caption>
                    <graphic xlink:href="jamanetwopen-e2339584-g004" position="float"/>
                  </fig>
                  <p>Analysis of subgroups jointly defined within BMI and subtype showed that, among patients with HR+/<italic>ERBB2</italic>â BC and overweight (nâ=â1054), non-Hispanic Black individuals (nâ=â69) had considerably worse RFS than non-Hispanic White individuals (nâ=â858) (HR, 2.12; 95% CI, 1.09-4.12), although the global test for race and ethnicity was not significant (global <italic>P</italic>â=â.08). This association was not statistically significant for OS. Within other subgroups defined by both BMI and subtype, there were no significant associations of race and ethnicity with RFS or OS.</p>
                </sec>
              </sec>
            </sec>
            <sec id="H1-4-ZOI231155">
              <title>Discussion</title>
              <p>We identified disease and patient subgroups with similarities and differences in survival among racial and ethnic groups for participants enrolled in 4 Alliance adjuvant chemotherapy clinical trials for eBC. While race and ethnicity, in general, were not associated with survival when stratified by subtype, non-Hispanic Black patients with HR+/<italic>ERBB2</italic>â tumors had worse RFS than non-Hispanic White patients. There were no OS differences by race and ethnicity in any subtype. We also observed survival differences within strata of some age groups: in middle-aged participants, non-Hispanic Black individuals had worse RFS than non-Hispanic White individuals. Among young participants, both non-Hispanic Black and Hispanic participants had worse OS than non-Hispanic White participants. Importantly, these survival differences existed even within clinical trial populations that ostensibly received standardized initial cancer care.</p>
              <p>Prior work within the National Comprehensive Cancer Network Breast Cancer Outcomes Database and in the Carolina Breast Cancer Study demonstrated that racial disparities vary by tumor subtype, with differences in survival between non-Hispanic Black and non-Hispanic White patients with HR+ BC and no differences for patients with triple negative or <italic>ERBB2</italic>+ BC.<sup><xref rid="zoi231155r17" ref-type="bibr">17</xref>,<xref rid="zoi231155r38" ref-type="bibr">38</xref></sup> However, these patients were not exclusively clinical trial participants. In contrast, there have been other analyses of survival differences in HR+ BCs within adjuvant clinical trials; however, unlike the present study, Hispanic patients and other race and ethnicity groups besides non-Hispanic Black and non-Hispanic White have not been specifically examined in these studies.<sup><xref rid="zoi231155r39" ref-type="bibr">39</xref>,<xref rid="zoi231155r40" ref-type="bibr">40</xref></sup> We would advocate for the dedicated study of these patients in gaining understanding of disparities facing patients with HR+ BC and have included these populations in our analyses.</p>
              <p>There are multiple plausible explanations for the differences observed between non-Hispanic Black and non-Hispanic White participants with HR+/<italic>ERBB2</italic>â BC in other studies and suggested in our study.<sup><xref rid="zoi231155r41" ref-type="bibr">41</xref></sup> Black patients are less likely to receive endocrine therapy, and some observational data suggests lower rates of adherence to endocrine therapy.<sup><xref rid="zoi231155r40" ref-type="bibr">40</xref>,<xref rid="zoi231155r42" ref-type="bibr">42</xref>,<xref rid="zoi231155r43" ref-type="bibr">43</xref></sup> Similarly, Black patients with HR+ BC are reported to have lower estrogen receptor staining levels.<sup><xref rid="zoi231155r44" ref-type="bibr">44</xref></sup> To better understand and address these factors, some investigators call for further biological delineation of HR+ subtype, evaluation of social determinants of health, and investigation into ancestry and country of origin in future studies.<sup><xref rid="zoi231155r41" ref-type="bibr">41</xref>,<xref rid="zoi231155r45" ref-type="bibr">45</xref></sup></p>
              <p>We found that, overall, young non-Hispanic Black and Hispanic patients have worse OS than young non-Hispanic White patients. It is reported that non-Hispanic Black and Hispanic women are more likely to be diagnosed with BC at a young age compared with non-Hispanic White women.<sup><xref rid="zoi231155r7" ref-type="bibr">7</xref>,<xref rid="zoi231155r46" ref-type="bibr">46</xref></sup> While we identified differences in OS for young non-Hispanic Black and Hispanic women compared with non-Hispanic White women, there was no association between race and ethnicity and RFS in these groups. One possible explanation for this may be related to comorbidities: young BC survivors, who typically have longer life expectancies than older survivors if cured from BC, are at increased risk of developing cardiac toxic effects, depression, and secondary cancers.<sup><xref rid="zoi231155r47" ref-type="bibr">47</xref></sup> Disparities in treatment of these conditions, as well as other nonâcancer-related comorbidities, may be driving the racial and ethnic disparities in OS but not RFS in younger patients. Additionally, while sample size was small, we observed that among older participants with HR+/<italic>ERBB2</italic>â BCs, Hispanic participants had more than 6 times worse RFS than non-Hispanic White participants. Both extremes of age and Hispanic ethnicity have been associated with reduced adherence to endocrine therapy, which may be a contributor.<sup><xref rid="zoi231155r18" ref-type="bibr">18</xref></sup></p>
              <p>It is unclear why Hispanic participants in this study had significantly worse RFS than non-Hispanic White participants if they had overweight, but there was no such association in patients with obesity. Obesity has been associated with increased BC mortality in several studies, although more recent studies suggest that this association holds in White women but not in Black women.<sup><xref rid="zoi231155r24" ref-type="bibr">24</xref>,<xref rid="zoi231155r25" ref-type="bibr">25</xref>,<xref rid="zoi231155r48" ref-type="bibr">48</xref>,<xref rid="zoi231155r49" ref-type="bibr">49</xref>,<xref rid="zoi231155r50" ref-type="bibr">50</xref>,<xref rid="zoi231155r51" ref-type="bibr">51</xref></sup> This is consistent with our data in the clinical trial setting and suggests that differences in obesity rates by race likely do not account for racial and ethnic disparities in BC survival.<sup><xref rid="zoi231155r52" ref-type="bibr">52</xref></sup> Of note, Hispanic ethnicity is underreported and underrepresented in clinical trials, and future studies with improved inclusion of Hispanic patients are necessary to confirm these findings.<sup><xref rid="zoi231155r26" ref-type="bibr">26</xref>,<xref rid="zoi231155r53" ref-type="bibr">53</xref></sup></p>
              <p>The strengths of this pooled analysis of clinical trials, including prospective collection of survival data with long follow-up, are particularly important given the outcomes of RFS and OS. Within each clinical trial, participants received similar initial treatment, and outcomes have been well ascertained. In addition to adjustment for baseline clinicopathologic risk factors, our analysis was adjusted for chemotherapy treatment received, thereby facilitating study of other factors associated with survival. By studying racial and ethnic disparities in survival in the clinical trial setting, which standardized initial care and treatment, our results emphasize that other factors, such as inequities in subsequent treatment, survivorship care, or biological differences, may contribute to these disparities. As such, this study extends the understanding of potential contributors to disparities in BC survival. We hope this will inform ongoing efforts to mitigate disparities in BC survival, such as patient navigation programs and the GETSET study<sup><xref rid="zoi231155r54" ref-type="bibr">54</xref></sup> (<ext-link xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT04379570" ext-link-type="uri">NCT04379570</ext-link>), as well as motivate the development of future interventions aimed at improving racial and ethnic inequities in long-term care after BC.<sup><xref rid="zoi231155r55" ref-type="bibr">55</xref>,<xref rid="zoi231155r56" ref-type="bibr">56</xref></sup></p>
              <sec id="H2-6-ZOI231155">
                <title>Limitations</title>
                <p>This study has limitations. Despite the pooled nature of this analysis, there are small sample sizes within certain strata. For example, small numbers of very young patients precluded our ability to specifically study women under the age of 40 years, a group that has been shown to exhibit differences in tumor genomics and worse BC outcomes. It is possible that such biologic heterogeneity affected outcomes in the group of women younger than 50 years.<sup><xref rid="zoi231155r17" ref-type="bibr">17</xref>,<xref rid="zoi231155r57" ref-type="bibr">57</xref>,<xref rid="zoi231155r58" ref-type="bibr">58</xref>,<xref rid="zoi231155r59" ref-type="bibr">59</xref></sup> The small sample sizes within certain subgroups, such as Hispanic participants and those with underweight BMI, likely impacts the precision of our findings. To mitigate this risk and limit the number of statistical comparisons made, we provide <italic>P</italic> values only for global tests comparing the main variables (race and ethnicity, age, tumor subtype, and BMI) rather than comparison of the many different levels of a variable. In the present study, it is possible that the global race and ethnicity variable was not significantly associated with RFS within any subtype due to sample size or the relatively low proportion of non-Hispanic Black and Hispanic participants, populations that are underrepresented in oncology clinical trials.<sup><xref rid="zoi231155r26" ref-type="bibr">26</xref>,<xref rid="zoi231155r60" ref-type="bibr">60</xref>,<xref rid="zoi231155r61" ref-type="bibr">61</xref></sup> Importantly, in this and many other ways, the clinical trial population does not represent typical clinical settings, and this may affect the generalizability of these data. Additionally, there was no adjustment made for multiple comparisons other than using a global test for the main variables of interest. However, throughout the manuscript, we report the testing that was done and provide estimates of observed effects.</p>
                <p>Information on cause of death could not be reliably ascertained from all 4 of the included studies and therefore we were unable to examine differences in BC-specific survival. Additionally, as specified previously, there is not documentation of how race and ethnicity were collected for participants in every trial, which may have led to misclassification of race and ethnicity in some participants.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI231155">
              <title>Conclusions</title>
              <p>In this cohort study of clinical trial participants treated for eBC, we observed worse survival among Black or Hispanic participants within subgroups defined by age, BMI, or tumor subtype. These data suggest that, in addition to addressing the social and structural factors that contribute to racial and ethnic disparities overall, it may be necessary to identify and address subgroup-specific mechanisms underlying the observed associations. It is critical to evaluate specific contributors to racial and ethnic disparities in survival as these may inform future interventions to improve these disparities.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI231155">
              <title>References</title>
              <ref id="zoi231155r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jatoi</surname><given-names>I</given-names></string-name>, <string-name><surname>Sung</surname><given-names>H</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name></person-group>. <article-title>The emergence of the racial disparity in U.S. breast-cancer mortality</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>25</issue>):<fpage>2349</fpage>-<lpage>2352</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp2200244</pub-id><?supplied-pmid 35713541?><pub-id pub-id-type="pmid">35713541</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Newman</surname><given-names>LA</given-names></string-name>, <string-name><surname>Griffith</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jatoi</surname><given-names>I</given-names></string-name>, <string-name><surname>Simon</surname><given-names>MS</given-names></string-name>, <string-name><surname>Crowe</surname><given-names>JP</given-names></string-name>, <string-name><surname>Colditz</surname><given-names>GA</given-names></string-name></person-group>. <article-title>Meta-analysis of survival in African American and White American patients with breast cancer: ethnicity compared with socioeconomic status</article-title>. <source>J Clin Oncol</source>. <year>2006</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1342</fpage>-<lpage>1349</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2005.03.3472</pub-id><?supplied-pmid 16549828?><pub-id pub-id-type="pmid">16549828</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hines</surname><given-names>RB</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>E</given-names></string-name>, <string-name><surname>Erickson</surname><given-names>S</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>SMM</given-names></string-name></person-group>. <article-title>Trends in breast cancer survival by race-ethnicity in Florida, 1990-2015</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2021</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1408</fpage>-<lpage>1415</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-1746</pub-id><?supplied-pmid 34210675?><pub-id pub-id-type="pmid">34210675</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nnorom</surname><given-names>SO</given-names></string-name>, <string-name><surname>Akinyemi</surname><given-names>O</given-names></string-name>, <string-name><surname>Tran</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Color or money?: the impact of socioeconomic status and race/ethnicity on breast cancer mortality</article-title>. <source>Am J Surg</source>. <year>2022</year>;<volume>224</volume>(<issue>6</issue>):<fpage>1403</fpage>-<lpage>1408</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjsurg.2022.07.013</pub-id><?supplied-pmid 36115705?><pub-id pub-id-type="pmid">36115705</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Prakash</surname><given-names>O</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>F</given-names></string-name>, <string-name><surname>Danos</surname><given-names>D</given-names></string-name>, <string-name><surname>Lassak</surname><given-names>A</given-names></string-name>, <string-name><surname>Scribner</surname><given-names>R</given-names></string-name>, <string-name><surname>Miele</surname><given-names>L</given-names></string-name></person-group>. <article-title>Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors</article-title>. <source>Front Public Health</source>. <year>2020</year>;<volume>8</volume>:<elocation-id>576964</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fpubh.2020.576964</pub-id><?supplied-pmid 33415093?><pub-id pub-id-type="pmid">33415093</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Azin</surname><given-names>A</given-names></string-name>, <string-name><surname>Tahmasebi</surname><given-names>H</given-names></string-name>, <string-name><surname>Brar</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Racial, ethnic and socioeconomic disparities in diagnosis, treatment, and survival of patients with breast cancer</article-title>. <source>Am J Surg</source>. <year>2023</year>;<volume>225</volume>(<issue>1</issue>):<fpage>154</fpage>-<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjsurg.2022.07.003</pub-id><?supplied-pmid 36030101?><pub-id pub-id-type="pmid">36030101</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Iqbal</surname><given-names>J</given-names></string-name>, <string-name><surname>Ginsburg</surname><given-names>O</given-names></string-name>, <string-name><surname>Rochon</surname><given-names>PA</given-names></string-name>, <string-name><surname>Sun</surname><given-names>P</given-names></string-name>, <string-name><surname>Narod</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>313</volume>(<issue>2</issue>):<fpage>165</fpage>-<lpage>173</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2014.17322</pub-id><?supplied-pmid 25585328?><pub-id pub-id-type="pmid">25585328</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>HE</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cancer statistics, 2022</article-title>. <source>CA Cancer J Clin</source>. <year>2022</year>;<volume>72</volume>(<issue>1</issue>):<fpage>7</fpage>-<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21708</pub-id><?supplied-pmid 35020204?><pub-id pub-id-type="pmid">35020204</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Goel</surname><given-names>N</given-names></string-name>, <string-name><surname>Yadegarynia</surname><given-names>S</given-names></string-name>, <string-name><surname>Lubarsky</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Racial and ethnic disparities in breast cancer survival: emergence of a clinically distinct Hispanic Black population</article-title>. <source>Ann Surg</source>. <year>2021</year>;<volume>274</volume>(<issue>3</issue>):<fpage>e269</fpage>-<lpage>e275</lpage>. doi:<pub-id pub-id-type="doi">10.1097/SLA.0000000000005004</pub-id><?supplied-pmid 34132699?><pub-id pub-id-type="pmid">34132699</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fedewa</surname><given-names>SA</given-names></string-name>, <string-name><surname>Ward</surname><given-names>EM</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>AK</given-names></string-name>, <string-name><surname>Edge</surname><given-names>SB</given-names></string-name></person-group>. <article-title>Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>(<issue>27</issue>):<fpage>4135</fpage>-<lpage>4141</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2009.27.2427</pub-id><?supplied-pmid 20697082?><pub-id pub-id-type="pmid">20697082</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nurgalieva</surname><given-names>ZZ</given-names></string-name>, <string-name><surname>Franzini</surname><given-names>L</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>RO</given-names></string-name>, <string-name><surname>Vernon</surname><given-names>SW</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CC</given-names></string-name>, <string-name><surname>Du</surname><given-names>XL</given-names></string-name></person-group>. <article-title>Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer</article-title>. <source>Med Oncol</source>. <year>2013</year>;<volume>30</volume>(<issue>1</issue>):<fpage>419</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s12032-012-0419-1</pub-id><?supplied-pmid 23292872?><pub-id pub-id-type="pmid">23292872</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chavez-MacGregor</surname><given-names>M</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>CA</given-names></string-name>, <string-name><surname>Lichtensztajn</surname><given-names>DY</given-names></string-name>, <string-name><surname>Giordano</surname><given-names>SH</given-names></string-name></person-group>. <article-title>Delayed initiation of adjuvant chemotherapy among patients with breast cancer</article-title>. <source>JAMA Oncol</source>. <year>2016</year>;<volume>2</volume>(<issue>3</issue>):<fpage>322</fpage>-<lpage>329</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2015.3856</pub-id><?supplied-pmid 26659132?><pub-id pub-id-type="pmid">26659132</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Albain</surname><given-names>KS</given-names></string-name>, <string-name><surname>Unger</surname><given-names>JM</given-names></string-name>, <string-name><surname>Crowley</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Coltman</surname><given-names>CA</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Hershman</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>(<issue>14</issue>):<fpage>984</fpage>-<lpage>992</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djp175</pub-id><?supplied-pmid 19584328?><pub-id pub-id-type="pmid">19584328</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Warner</surname><given-names>ET</given-names></string-name>, <string-name><surname>Tamimi</surname><given-names>RM</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>ME</given-names></string-name>, <etal/></person-group>. <article-title>Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>20</issue>):<fpage>2254</fpage>-<lpage>2261</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2014.57.1349</pub-id><?supplied-pmid 25964252?><pub-id pub-id-type="pmid">25964252</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Li</surname><given-names>CI</given-names></string-name>, <string-name><surname>Malone</surname><given-names>KE</given-names></string-name>, <string-name><surname>Daling</surname><given-names>JR</given-names></string-name></person-group>. <article-title>Differences in breast cancer stage, treatment, and survival by race and ethnicity</article-title>. <source>Arch Intern Med</source>. <year>2003</year>;<volume>163</volume>(<issue>1</issue>):<fpage>49</fpage>-<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.163.1.49</pub-id><?supplied-pmid 12523916?><pub-id pub-id-type="pmid">12523916</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ooi</surname><given-names>SL</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>ME</given-names></string-name>, <string-name><surname>Li</surname><given-names>CI</given-names></string-name></person-group>. <article-title>Disparities in breast cancer characteristics and outcomes by race/ethnicity</article-title>. <source>Breast Cancer Res Treat</source>. <year>2011</year>;<volume>127</volume>(<issue>3</issue>):<fpage>729</fpage>-<lpage>738</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-010-1191-6</pub-id><?supplied-pmid 21076864?><pub-id pub-id-type="pmid">21076864</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Partridge</surname><given-names>AH</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>ME</given-names></string-name>, <string-name><surname>Warner</surname><given-names>ET</given-names></string-name>, <etal/></person-group>. <article-title>Subtype-dependent relationship between young age at diagnosis and breast cancer survival</article-title>. <source>J Clin Oncol</source>. <year>2016</year>;<volume>34</volume>(<issue>27</issue>):<fpage>3308</fpage>-<lpage>3314</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2015.65.8013</pub-id><?supplied-pmid 27480155?><pub-id pub-id-type="pmid">27480155</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Partridge</surname><given-names>AH</given-names></string-name>, <string-name><surname>Wang</surname><given-names>PS</given-names></string-name>, <string-name><surname>Winer</surname><given-names>EP</given-names></string-name>, <string-name><surname>Avorn</surname><given-names>J</given-names></string-name></person-group>. <article-title>Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2003</year>;<volume>21</volume>(<issue>4</issue>):<fpage>602</fpage>-<lpage>606</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2003.07.071</pub-id><?supplied-pmid 12586795?><pub-id pub-id-type="pmid">12586795</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sedrak</surname><given-names>MS</given-names></string-name>, <string-name><surname>Sun</surname><given-names>C-L</given-names></string-name>, <string-name><surname>Ji</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Low-intensity adjuvant chemotherapy for breast cancer in older women: results from the prospective multicenter HOPE Trial</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>(<issue>2</issue>):<fpage>316</fpage>-<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.22.01440</pub-id><?supplied-pmid 36455189?><pub-id pub-id-type="pmid">36455189</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gnerlich</surname><given-names>JL</given-names></string-name>, <string-name><surname>Deshpande</surname><given-names>AD</given-names></string-name>, <string-name><surname>Jeffe</surname><given-names>DB</given-names></string-name>, <string-name><surname>Sweet</surname><given-names>A</given-names></string-name>, <string-name><surname>White</surname><given-names>N</given-names></string-name>, <string-name><surname>Margenthaler</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease</article-title>. <source>J Am Coll Surg</source>. <year>2009</year>;<volume>208</volume>(<issue>3</issue>):<fpage>341</fpage>-<lpage>347</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2008.12.001</pub-id><?supplied-pmid 19317994?><pub-id pub-id-type="pmid">19317994</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fredholm</surname><given-names>H</given-names></string-name>, <string-name><surname>Eaker</surname><given-names>S</given-names></string-name>, <string-name><surname>Frisell</surname><given-names>J</given-names></string-name>, <string-name><surname>Holmberg</surname><given-names>L</given-names></string-name>, <string-name><surname>Fredriksson</surname><given-names>I</given-names></string-name>, <string-name><surname>Lindman</surname><given-names>H</given-names></string-name></person-group>. <article-title>Breast cancer in young women: poor survival despite intensive treatment</article-title>. <source>PLoS One</source>. <year>2009</year>;<volume>4</volume>(<issue>11</issue>):<elocation-id>e7695</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0007695</pub-id><?supplied-pmid 19907646?><pub-id pub-id-type="pmid">19907646</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Freedman</surname><given-names>RA</given-names></string-name>, <string-name><surname>Keating</surname><given-names>NL</given-names></string-name>, <string-name><surname>Lin</surname><given-names>NU</given-names></string-name>, <etal/></person-group>. <article-title>Breast cancer-specific survival by age: worse outcomes for the oldest patients</article-title>. <source>Cancer</source>. <year>2018</year>;<volume>124</volume>(<issue>10</issue>):<fpage>2184</fpage>-<lpage>2191</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.31308</pub-id><?supplied-pmid 29499074?><pub-id pub-id-type="pmid">29499074</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Marret</surname><given-names>H</given-names></string-name>, <string-name><surname>Perrotin</surname><given-names>F</given-names></string-name>, <string-name><surname>Bougnoux</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>2001</year>;<volume>66</volume>(<issue>1</issue>):<fpage>17</fpage>-<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1023/A:1010699912768</pub-id><?supplied-pmid 11368406?><pub-id pub-id-type="pmid">11368406</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Picon-Ruiz</surname><given-names>M</given-names></string-name>, <string-name><surname>Morata-Tarifa</surname><given-names>C</given-names></string-name>, <string-name><surname>Valle-Goffin</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>ER</given-names></string-name>, <string-name><surname>Slingerland</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention</article-title>. <source>CA Cancer J Clin</source>. <year>2017</year>;<volume>67</volume>(<issue>5</issue>):<fpage>378</fpage>-<lpage>397</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21405</pub-id><?supplied-pmid 28763097?><pub-id pub-id-type="pmid">28763097</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jiralerspong</surname><given-names>S</given-names></string-name>, <string-name><surname>Goodwin</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Obesity and breast cancer prognosis: evidence, challenges, and opportunities</article-title>. <source>J Clin Oncol</source>. <year>2016</year>;<volume>34</volume>(<issue>35</issue>):<fpage>4203</fpage>-<lpage>4216</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2016.68.4480</pub-id><?supplied-pmid 27903149?><pub-id pub-id-type="pmid">27903149</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Keegan</surname><given-names>G</given-names></string-name>, <string-name><surname>Crown</surname><given-names>A</given-names></string-name>, <string-name><surname>DiMaggio</surname><given-names>C</given-names></string-name>, <string-name><surname>Joseph</surname><given-names>KA</given-names></string-name></person-group>. <article-title>Insufficient reporting of race and ethnicity in breast cancer clinical trials</article-title>. <source>Ann Surg Oncol</source>. Published online September 1, <year>2023</year>. doi:<pub-id pub-id-type="doi">10.1245/s10434-023-14201-z</pub-id><?supplied-pmid 37658271?><pub-id pub-id-type="pmid">37658271</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Muss</surname><given-names>HB</given-names></string-name>, <string-name><surname>Berry</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cirrincione</surname><given-names>CT</given-names></string-name>, <etal/>; <collab>CALGB Investigators</collab></person-group>. <article-title>Adjuvant chemotherapy in older women with early-stage breast cancer</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>20</issue>):<fpage>2055</fpage>-<lpage>2065</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0810266</pub-id><?supplied-pmid 19439741?><pub-id pub-id-type="pmid">19439741</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Perez</surname><given-names>EA</given-names></string-name>, <string-name><surname>Suman</surname><given-names>VJ</given-names></string-name>, <string-name><surname>Davidson</surname><given-names>NE</given-names></string-name>, <etal/></person-group>. <article-title>Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>34</issue>):<fpage>4491</fpage>-<lpage>4497</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2011.36.7045</pub-id><?supplied-pmid 22042958?><pub-id pub-id-type="pmid">22042958</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Shulman</surname><given-names>LN</given-names></string-name>, <string-name><surname>Berry</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cirrincione</surname><given-names>CT</given-names></string-name>, <etal/></person-group>. <article-title>Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>22</issue>):<fpage>2311</fpage>-<lpage>2317</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.53.7142</pub-id><?supplied-pmid 24934787?><pub-id pub-id-type="pmid">24934787</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Citron</surname><given-names>ML</given-names></string-name>, <string-name><surname>Berry</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cirrincione</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741</article-title>. <source>J Clin Oncol</source>. <year>2003</year>;<volume>21</volume>(<issue>8</issue>):<fpage>1431</fpage>-<lpage>1439</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2003.09.081</pub-id><?supplied-pmid 12668651?><pub-id pub-id-type="pmid">12668651</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r31">
                <label>31</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>Zierle-Ghosh</surname><given-names>A</given-names></string-name>, <string-name><surname>Jan</surname><given-names>A</given-names></string-name></person-group>. <source>Physiology, Body Mass Index</source>. <publisher-name>StatPearls Publishing LLC</publisher-name>; <year>2023</year>.</mixed-citation>
              </ref>
              <ref id="zoi231155r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Tolaney</surname><given-names>SM</given-names></string-name>, <string-name><surname>Garrett-Mayer</surname><given-names>E</given-names></string-name>, <string-name><surname>White</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>24</issue>):<fpage>2720</fpage>-<lpage>2731</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.20.03613</pub-id><?supplied-pmid 34003702?><pub-id pub-id-type="pmid">34003702</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Shuster</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Median follow-up in clinical trials</article-title>. <source>J Clin Oncol</source>. <year>1991</year>;<volume>9</volume>(<issue>1</issue>):<fpage>191</fpage>-<lpage>192</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.1991.9.1.191</pub-id><?supplied-pmid 1985169?><pub-id pub-id-type="pmid">1985169</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaplan</surname><given-names>EL</given-names></string-name>, <string-name><surname>Meier</surname><given-names>P</given-names></string-name></person-group>. <article-title>Nonparametric estimation from incomplete observations</article-title>. <source>J Am Stat Assoc</source>. <year>1958</year>;<volume>53</volume>(<issue>282</issue>):<fpage>457</fpage>-<lpage>481</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cox</surname><given-names>DR</given-names></string-name></person-group>. <article-title>Regression models and life-tables</article-title>. <source>J Royal Stat Soc. Series B (Methodological)</source>. <year>1972</year>;<volume>34</volume>(<issue>2</issue>):<fpage>187</fpage>-<lpage>220</lpage>.</mixed-citation>
              </ref>
              <ref id="zoi231155r36">
                <label>36</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>Fleiss</surname><given-names>JL</given-names></string-name>, <string-name><surname>Levin</surname><given-names>B</given-names></string-name>, <string-name><surname>Paik</surname><given-names>MC</given-names></string-name></person-group>. <source>Statistical Methods for Rates and Proportions</source>. 2nd ed. John Wiley &amp; Sons; <year>1981</year>.</mixed-citation>
              </ref>
              <ref id="zoi231155r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lewis</surname><given-names>S</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>M</given-names></string-name></person-group>. <article-title>Forest plots: trying to see the wood and the trees</article-title>. <source>BMJ</source>. <year>2001</year>;<volume>322</volume>(<issue>7300</issue>):<fpage>1479</fpage>-<lpage>1480</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.322.7300.1479</pub-id><?supplied-pmid 11408310?><pub-id pub-id-type="pmid">11408310</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>OâBrien</surname><given-names>KM</given-names></string-name>, <string-name><surname>Cole</surname><given-names>SR</given-names></string-name>, <string-name><surname>Tse</surname><given-names>CK</given-names></string-name>, <etal/></person-group>. <article-title>Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study</article-title>. <source>Clin Cancer Res</source>. <year>2010</year>;<volume>16</volume>(<issue>24</issue>):<fpage>6100</fpage>-<lpage>6110</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1533</pub-id><?supplied-pmid 21169259?><pub-id pub-id-type="pmid">21169259</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kim</surname><given-names>G</given-names></string-name>, <string-name><surname>Pastoriza</surname><given-names>JM</given-names></string-name>, <string-name><surname>Qin</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Racial disparity in distant recurrence-free survival in patients with localized breast cancer: a pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials</article-title>. <source>Cancer</source>. <year>2022</year>;<volume>128</volume>(<issue>14</issue>):<fpage>2728</fpage>-<lpage>2735</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.34241</pub-id><?supplied-pmid 35578919?><pub-id pub-id-type="pmid">35578919</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sadigh</surname><given-names>G</given-names></string-name>, <string-name><surname>Gray</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Sparano</surname><given-names>JA</given-names></string-name>, <etal/></person-group>. <article-title>Assessment of racial disparity in survival outcomes for early hormone receptor-positive breast cancer after adjusting for insurance status and neighborhood deprivation: a post hoc analysis of a randomized clinical trial</article-title>. <source>JAMA Oncol</source>. <year>2022</year>;<volume>8</volume>(<issue>4</issue>):<fpage>579</fpage>-<lpage>586</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2021.7656</pub-id><?supplied-pmid 35175284?><pub-id pub-id-type="pmid">35175284</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jones</surname><given-names>VC</given-names></string-name>, <string-name><surname>Kruper</surname><given-names>L</given-names></string-name>, <string-name><surname>Mortimer</surname><given-names>J</given-names></string-name>, <string-name><surname>Ashing</surname><given-names>KT</given-names></string-name>, <string-name><surname>Seewaldt</surname><given-names>VL</given-names></string-name></person-group>. <article-title>Understanding drivers of the Black:White breast cancer mortality gap: a call for more robust definitions</article-title>. <source>Cancer</source>. <year>2022</year>;<volume>128</volume>(<issue>14</issue>):<fpage>2695</fpage>-<lpage>2697</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.34243</pub-id><?supplied-pmid 35578909?><pub-id pub-id-type="pmid">35578909</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lund</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Brawley</surname><given-names>OP</given-names></string-name>, <string-name><surname>Ward</surname><given-names>KC</given-names></string-name>, <string-name><surname>Young</surname><given-names>JL</given-names></string-name>, <string-name><surname>Gabram</surname><given-names>SS</given-names></string-name>, <string-name><surname>Eley</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Parity and disparity in first course treatment of invasive breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>2008</year>;<volume>109</volume>(<issue>3</issue>):<fpage>545</fpage>-<lpage>557</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-007-9675-8</pub-id><?supplied-pmid 17659438?><pub-id pub-id-type="pmid">17659438</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Reeder-Hayes</surname><given-names>KE</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>BE</given-names></string-name>, <string-name><surname>Baggett</surname><given-names>CD</given-names></string-name>, <etal/></person-group>. <article-title>Race, geography, and risk of breast cancer treatment delays: a population-based study 2004-2015</article-title>. <source>Cancer</source>. <year>2023</year>;<volume>129</volume>(<issue>6</issue>):<fpage>925</fpage>-<lpage>933</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.34573</pub-id><?supplied-pmid 36683417?><pub-id pub-id-type="pmid">36683417</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Purrington</surname><given-names>KS</given-names></string-name>, <string-name><surname>Gorski</surname><given-names>D</given-names></string-name>, <string-name><surname>Simon</surname><given-names>MS</given-names></string-name>, <etal/></person-group>. <article-title>Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers</article-title>. <source>Breast Cancer Res Treat</source>. <year>2020</year>;<volume>181</volume>(<issue>1</issue>):<fpage>145</fpage>-<lpage>154</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-020-05607-4</pub-id><?supplied-pmid 32236827?><pub-id pub-id-type="pmid">32236827</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Borrell</surname><given-names>LN</given-names></string-name>, <string-name><surname>Elhawary</surname><given-names>JR</given-names></string-name>, <string-name><surname>Fuentes-Afflick</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Race and genetic ancestry in medicineâa time for reckoning with racism</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>5</issue>):<fpage>474</fpage>-<lpage>480</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMms2029562</pub-id><?supplied-pmid 33406325?><pub-id pub-id-type="pmid">33406325</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Romero-Cordoba</surname><given-names>SL</given-names></string-name>, <string-name><surname>Salido-Guadarrama</surname><given-names>I</given-names></string-name>, <string-name><surname>Rebollar-Vega</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Comprehensive omic characterization of breast cancer in Mexican-Hispanic women</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>2245</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-22478-5</pub-id><?supplied-pmid 33854067?><pub-id pub-id-type="pmid">33854067</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Tesch</surname><given-names>ME</given-names></string-name>, <string-name><surname>Partridge</surname><given-names>AH</given-names></string-name></person-group>. <article-title>Treatment of breast cancer in young adults</article-title>. <source>Am Soc Clin Oncol Educ Book</source>. <year>2022</year>;<volume>42</volume>(<issue>42</issue>):<fpage>1</fpage>-<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1200/EDBK_360970</pub-id><?supplied-pmid 35580291?><pub-id pub-id-type="pmid">35580291</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname><given-names>H</given-names></string-name>, <string-name><surname>Malone</surname><given-names>KE</given-names></string-name>, <etal/></person-group>. <article-title>Obesity and survival among Black women and White women 35 to 64 years of age at diagnosis with invasive breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>25</issue>):<fpage>3358</fpage>-<lpage>3365</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2010.34.2048</pub-id><?supplied-pmid 21788570?><pub-id pub-id-type="pmid">21788570</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Obesity and weight change in relation to breast cancer survival</article-title>. <source>Breast Cancer Res Treat</source>. <year>2010</year>;<volume>122</volume>(<issue>3</issue>):<fpage>823</fpage>-<lpage>833</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-009-0708-3</pub-id><?supplied-pmid 20058068?><pub-id pub-id-type="pmid">20058068</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Caan</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Kwan</surname><given-names>ML</given-names></string-name>, <string-name><surname>Hartzell</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer</article-title>. <source>Cancer Causes Control</source>. <year>2008</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1319</fpage>-<lpage>1328</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10552-008-9203-0</pub-id><?supplied-pmid 18752034?><pub-id pub-id-type="pmid">18752034</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chan</surname><given-names>DSM</given-names></string-name>, <string-name><surname>Vieira</surname><given-names>AR</given-names></string-name>, <string-name><surname>Aune</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1901</fpage>-<lpage>1914</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdu042</pub-id><?supplied-pmid 24769692?><pub-id pub-id-type="pmid">24769692</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ogden</surname><given-names>CL</given-names></string-name>, <string-name><surname>Carroll</surname><given-names>MD</given-names></string-name>, <string-name><surname>Curtin</surname><given-names>LR</given-names></string-name>, <string-name><surname>McDowell</surname><given-names>MA</given-names></string-name>, <string-name><surname>Tabak</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Flegal</surname><given-names>KM</given-names></string-name></person-group>. <article-title>Prevalence of overweight and obesity in the United States, 1999-2004</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>295</volume>(<issue>13</issue>):<fpage>1549</fpage>-<lpage>1555</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.295.13.1549</pub-id><?supplied-pmid 16595758?><pub-id pub-id-type="pmid">16595758</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bazan</surname><given-names>JG</given-names></string-name>, <string-name><surname>Obeng-Gyasi</surname><given-names>S</given-names></string-name>, <string-name><surname>Gamez</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Reporting of race and Hispanic ethnicity in breast cancer studies from the National Cancer Database</article-title>. <source>JAMA Oncol</source>. <year>2022</year>;<volume>8</volume>(<issue>10</issue>):<fpage>1507</fpage>-<lpage>1509</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2022.3527</pub-id><?supplied-pmid 36006628?><pub-id pub-id-type="pmid">36006628</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r54">
                <label>54</label>
                <mixed-citation publication-type="webpage">Get Set. Accessed September 25, 2023. <ext-link xlink:href="https://getsetstudy.org/" ext-link-type="uri">https://getsetstudy.org/</ext-link></mixed-citation>
              </ref>
              <ref id="zoi231155r55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sheppard</surname><given-names>VB</given-names></string-name>, <string-name><surname>Isaacs</surname><given-names>C</given-names></string-name>, <string-name><surname>Luta</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship</article-title>. <source>Breast Cancer Res Treat</source>. <year>2013</year>;<volume>139</volume>(<issue>1</issue>):<fpage>207</fpage>-<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-013-2520-3</pub-id><?supplied-pmid 23588954?><pub-id pub-id-type="pmid">23588954</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Simon</surname><given-names>MA</given-names></string-name>, <string-name><surname>Trosman</surname><given-names>JR</given-names></string-name>, <string-name><surname>Rapkin</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Systematic patient navigation strategies to scale breast cancer disparity reduction by improved cancer prevention and care delivery processes</article-title>. <source>JCO Oncol Pract</source>. <year>2020</year>;<volume>16</volume>(<issue>12</issue>):<fpage>e1462</fpage>-<lpage>e1470</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JOP.19.00314</pub-id><?supplied-pmid 32574137?><pub-id pub-id-type="pmid">32574137</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Waks</surname><given-names>AG</given-names></string-name>, <string-name><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name><surname>Jain</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Somatic and germline genomic alterations in very young women with breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>2022</year>;<volume>28</volume>(<issue>11</issue>):<fpage>2339</fpage>-<lpage>2348</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2572</pub-id><?supplied-pmid 35101884?><pub-id pub-id-type="pmid">35101884</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Luen</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Viale</surname><given-names>G</given-names></string-name>, <string-name><surname>Nik-Zainal</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Genomic characterisation of hormone receptor-positive breast cancer arising in very young women</article-title>. <source>Ann Oncol</source>. <year>2023</year>;<volume>34</volume>(<issue>4</issue>):<fpage>397</fpage>-<lpage>409</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annonc.2023.01.009</pub-id><?supplied-pmid 36709040?><pub-id pub-id-type="pmid">36709040</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>GuzmÃ¡n-Arocho</surname><given-names>YD</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>SM</given-names></string-name>, <string-name><surname>Garber</surname><given-names>JE</given-names></string-name>, <etal/></person-group>. <article-title>Clinicopathological features and <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation status in a prospective cohort of young women with breast cancer</article-title>. <source>Br J Cancer</source>. <year>2022</year>;<volume>126</volume>(<issue>2</issue>):<fpage>302</fpage>-<lpage>309</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41416-021-01597-2</pub-id><?supplied-pmid 34703009?><pub-id pub-id-type="pmid">34703009</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Loree</surname><given-names>JM</given-names></string-name>, <string-name><surname>Anand</surname><given-names>S</given-names></string-name>, <string-name><surname>Dasari</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018</article-title>. <source>JAMA Oncol</source>. <year>2019</year>;<volume>5</volume>(<issue>10</issue>):<fpage>e191870</fpage>-<lpage>e191870</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2019.1870</pub-id><?supplied-pmid 31415071?><pub-id pub-id-type="pmid">31415071</pub-id></mixed-citation>
              </ref>
              <ref id="zoi231155r61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Aldrighetti</surname><given-names>CM</given-names></string-name>, <string-name><surname>Niemierko</surname><given-names>A</given-names></string-name>, <string-name><surname>Van Allen</surname><given-names>E</given-names></string-name>, <string-name><surname>Willers</surname><given-names>H</given-names></string-name>, <string-name><surname>Kamran</surname><given-names>SC</given-names></string-name></person-group>. <article-title>Racial and ethnic disparities among participants in precision oncology clinical studies</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>11</issue>):<elocation-id>e2133205</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.33205</pub-id><?supplied-pmid 34748007?><pub-id pub-id-type="pmid">34748007</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI231155-1">
              <supplementary-material id="note-ZOI231155-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p><bold>eMethods.</bold> Supplemental Methods</p>
                  <p><bold>eFigure 1.</bold> Kaplan-Meier Estimates of Recurrence-Free Survival in Breast Cancer Subtype by Race and Ethnicity</p>
                  <p><bold>eFigure 2.</bold> Kaplan-Meier Estimates of Overall Survival in Breast Cancer Subtype by Race and Ethnicity</p>
                  <p><bold>eFigure 3.</bold> Kaplan-Meier Estimates of Recurrence-Free Survival in Age Category by Race and Ethnicity</p>
                  <p><bold>eFigure 4.</bold> Kaplan-Meier Estimates of Overall Survival in Age Category by Race and Ethnicity</p>
                  <p><bold>eFigure 5.</bold> Kaplan-Meier Estimates of Recurrence-Free Survival in Body Mass Index (BMI) Category by Race and Ethnicity</p>
                  <p><bold>eFigure 6.</bold> Kaplan-Meier Estimates of Overall Survival in Body Mass Index (BMI) Category by Race and Ethnicity</p>
                  <p>
eReferences.
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2339584-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2339584-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
